Participants in the cyclosporine group had a lower 1‐year PTDM incidence that failed to reach statistical significance, but also an increased probability of acute rejection [ 58 ].
← all excerpts
Management of post-transplant diabetes: immunosuppression, early prevention, and novel antidiabetics.
1
—
—